Does Prepregnancy Weight or Maternal BMI at Betamethasone Administration Impact Late Preterm Respiratory Morbidity?...SMFM 39th Annual Meeting, The Pregnancy Meeting, February 11–16, 2019, Las Vegas, Nevada.
Objective We sought to determine if maternal prepregnancy body mass index (BMI) is a risk factor for neonatal respiratory morbidity and to determine if increasing BMI decreased the efficacy of betamethasone (BMZ). Study Design This was a secondary analysis of the Antenatal Late Preterm Steroids tr...
| Publicado en: | American Journal of Perinatology Vol. 37; no. 4; pp. 365 - 370 |
|---|---|
| Autores principales: | , , |
| Formato: | proceedings research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Thieme Medical Publishing Inc.
2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142065045&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 142065045 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 07351631 GQK jtl: American Journal of Perinatology issn: 07351631 maglogo: N pubinfo: dt: 2020 vid: 37 iid: 4 pid: 2811 pub: Thieme Medical Publishing Inc. place: New York, New York artinfo: ui: 142065045 142065045 142065045 10.1055/s-0039-1696644 142065045 ppf: 365 ppct: 5 formats: tig: atl: Does Prepregnancy Weight or Maternal BMI at Betamethasone Administration Impact Late Preterm Respiratory Morbidity?...SMFM 39th Annual Meeting, The Pregnancy Meeting, February 11–16, 2019, Las Vegas, Nevada. aug: au: Bicocca, Matthew J. Blackwell, Sean C. Sibai, Baha M. affil: Department of Obstetrics, Gynecology and Reproductive Sciences The University of Texas Health Science Center at Houston, 6431 Fannin Street, Suite 3.264, Houston, TX 77030 sug: subj: Childbirth, Premature Respiration Disorders Drug Therapy Morbidity Prevention and Control Betamethasone Administration and Dosage Mothers Obesity Complications Treatment Outcomes Human Infant, Newborn Secondary Analysis Pregnancy Female Placebos Administration and Dosage Stratified Random Sample Odds Ratio Confidence Intervals Body Weight Randomized Controlled Trials Congresses and Conferences Nevada Nevada Random Assignment Betamethasone Pharmacodynamics Body Mass Index Risk Assessment Infant, Newborn: birth-1 month Female ab: Objective We sought to determine if maternal prepregnancy body mass index (BMI) is a risk factor for neonatal respiratory morbidity and to determine if increasing BMI decreased the efficacy of betamethasone (BMZ). Study Design This was a secondary analysis of the Antenatal Late Preterm Steroids trial, double-blind, randomized controlled trial involving 2,831 women between 34 0/7 and 36 5/7 weeks who received BMZ or a matching placebo. We compared the rate of neonatal respiratory morbidity among prepregnancy BMI classes in both the placebo and treatment groups. We also stratified the treatment effect by maternal BMI at the time of delivery. Results A total of 2,822 women were identified with maternal weight recorded at delivery; 2,740 women also had self-reported prepregnancy weight available. When stratified by prepregnancy BMI class, there was no difference in neonatal respiratory morbidity in the BMZ or in placebo groups. When analyzed by BMI at delivery, there was no difference in the rate of neonatal respiratory morbidity, and BMI was not a predictor of treatment response (odds ratio = 1.00, 95% confidence interval = 0.99–1.02). Conclusion Maternal prepregnancy BMI is not associated with late preterm neonatal respiratory morbidity. Maternal obesity does not decrease the efficacy of BMZ for preventing late preterm neonatal respiratory morbidity. pubtype: Academic Journal doctype: proceedings research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|